CohBar Inc (CWBR):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:CohBar Inc (CWBR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8275
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:50
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
CohBar Inc (CohBar) is a developer of mitochondria based therapeutics. The company develops a class of drugs to treat a wide range of diseases associated with aging and metabolic dysfunction such as non-alcoholic steatohepatitis, obesity, type 2 diabetes, cancer, cardiovascular disease and CNS disorders. It offers MDP drugs such as MOTS-c for regulation of metabolism and therapeutic potential for diabetes mellitus, obesity, fatty liver and cancers; SHLP-6 for cancer; humanin against Alzheimer’s disease, atherosclerosis, myocardial and cerebral ischemia and diabetes; and SHLP-2 for Alzheimer’s disease. CohBar’s expertise comprises cellular and mitochondrial genetics and biology, metabolism, the biology of aging, drug discovery, development and commercialization. The company also conducts scientific research in the fields of age-related diseases, mitochondrial genomics and biology, longevity, metabolism and MDP’s. CohBar is headquartered in Menlo Park, California, the US.

CohBar Inc (CWBR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
CohBar Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CohBar Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
CohBar Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CohBar Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
CohBar Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
CohBar Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
CohBar Raises USD0.5 Million in Venture Financing 11
Licensing Agreements 12
CohBar Enters Into Licensing Agreement With Regents Of The University Of California 12
Equity Offering 14
CohBar Raises USD20 Million in Public Offering of Shares 14
CohBar Plans to Raise up to USD100 Million in Public Offering of Securities 15
CohBar Plans to Raise up to USD18.7 Million in Private Placement of Shares 16
CohBar Raises USD5.2 Million in Private Placement of Units 17
CohBar Raises USD5.3 Million in Private Placement of Shares upon Exercise of Warrants 18
CohBar Raises USD11 Million in IPO of Units 19
CohBar Raises USD2.7 Million in Private Placement of Units 20
CohBar Raises USD2.7 Million in Private Placement of Series B Preferred Stock 21
CohBar Raises USD1.8 Million in Private Placement of Series A Preferred Stock 22
Debt Offering 23
CohBar Raises USD1.8 Million in Second and Final Tranche of Private Placement of Promissory Notes 23
CohBar Raises USD2.14 Million in First Tranche of Private Placement of Promissory Notes 24
CohBar Raises USD0.07 Million in Private Placement of Convertibles Notes 25
CohBar Inc – Key Competitors 26
CohBar Inc – Key Employees 27
CohBar Inc – Locations And Subsidiaries 28
Head Office 28
Recent Developments 29
Financial Announcements 29
Aug 14, 2018: CohBar announces second quarter 2018 financial results 29
May 15, 2018: CohBar Reports First Quarter 2018 Financial Results 31
Apr 02, 2018: CohBar Announces Fourth Quarter 2017 Financial Results 32
Nov 13, 2017: CohBar Announces Third Quarter 2017 Financial Results 34
Aug 14, 2017: CohBar Announces Second Quarter 2017 Financial Results 36
May 15, 2017: CohBar Announces First Quarter 2017 Financial Results 37
Mar 22, 2017: CohBar Announces Fourth Quarter 2016 Financial Results 39
Corporate Communications 40
Jun 07, 2018: CohBar Announces the Appointment of Dr. Philippe Calais to its Board 40
Dec 13, 2017: CohBar Announces Approval for Listing on the NASDAQ Capital MarketNASDAQ Trading to Begin on December 15, 2017 Under Existing Ticker Symbol CWBR 41
Dec 07, 2017: CohBar Announces the Appointment of Dr. John Amatruda to its Board 42
Product News 43
05/29/2018: CohBar to Present CB4211 Novel Mechanism of Action at American Diabetes Association 78th Scientific Sessions 43
Clinical Trials 44
Jun 25, 2018: CohBar Presents Preclinical Data on Mechanism of Action for its Lead Candidate, CB4211, at American Diabetes Association 78th Scientific Sessions 44
Oct 23, 2017: CohBar Presents Preclinical Data on CB4211 Program for NASH at the AASLD Liver Meeting 2017 45
Oct 04, 2017: CohBar Announces Scientific Presentation on Preclinical data of drug candidate CB-4211 for NASH Study at the AASLD Liver Meeting 2017 46
Feb 21, 2017: CohBar Announces Positive Results from Preclinical NASH Study of CB-4211 47
Other Significant Developments 48
Sep 25, 2018: CohBar engages LifeSci advisors as investor relations partner 48
Jun 27, 2018: CohBar Added to Russell 2000 Index 49
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50

List of Tables
CohBar Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
CohBar Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CohBar Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
CohBar Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CohBar Inc, Deals By Therapy Area, 2012 to YTD 2018 9
CohBar Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
CohBar Raises USD0.5 Million in Venture Financing 11
CohBar Enters Into Licensing Agreement With Regents Of The University Of California 12
CohBar Raises USD20 Million in Public Offering of Shares 14
CohBar Plans to Raise up to USD100 Million in Public Offering of Securities 15
CohBar Plans to Raise up to USD18.7 Million in Private Placement of Shares 16
CohBar Raises USD5.2 Million in Private Placement of Units 17
CohBar Raises USD5.3 Million in Private Placement of Shares upon Exercise of Warrants 18
CohBar Raises USD11 Million in IPO of Units 19
CohBar Raises USD2.7 Million in Private Placement of Units 20
CohBar Raises USD2.7 Million in Private Placement of Series B Preferred Stock 21
CohBar Raises USD1.8 Million in Private Placement of Series A Preferred Stock 22
CohBar Raises USD1.8 Million in Second and Final Tranche of Private Placement of Promissory Notes 23
CohBar Raises USD2.14 Million in First Tranche of Private Placement of Promissory Notes 24
CohBar Raises USD0.07 Million in Private Placement of Convertibles Notes 25
CohBar Inc, Key Competitors 26
CohBar Inc, Key Employees 27

List of Figures
CohBar Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
CohBar Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
CohBar Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
CohBar Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
CohBar Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
CohBar Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
CohBar Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
CohBar Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[CohBar Inc (CWBR):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Yungjin Pharm Co Ltd (003520):製薬・医療:M&Aディール及び事業提携情報
    Summary Yungjin Pharm Co Ltd (Yungjin), a subsidiary of KT&G Corp is a pharmaceutical company that develops, manufactures and distributes active pharmaceutical ingredients, formulations and tonic drinks. The company provides API products such as cephalosporins and other general products. It also off …
  • Debiopharm International SA:医療機器:M&Aディール及び事業提携情報
    Summary Debiopharm International SA (Debiopharm), a subsidiary of Debiopharm Group is a biopharmaceutical company that develops prescription drugs. The company offers a range of licensing and drug development solutions. It evaluates, searches, and in-licenses promising drug candidates for developmen …
  • Jamaica Public Service Co Ltd:発電所・企業SWOT分析
    Jamaica Public Service Co Ltd – Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …
  • Teijin Ltd (3401):医療機器:M&Aディール及び事業提携情報
    Summary Teijin Ltd (Teijin) is a technology driven holding company offering solutions in the areas of information and electronics, healthcare, environment and energy and safety and protection. It focuses on the manufacture and sale of aramid fiber, carbon fiber products, synthetic fiber, films, poly …
  • Theravance Biopharma Inc (TBPH):企業の財務・戦略的SWOT分析
    Theravance Biopharma Inc (TBPH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • HORNBACH-Baumarkt-AG (HBM):企業の財務・戦略的SWOT分析
    HORNBACH-Baumarkt-AG (HBM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Healthland Inc:医療機器:M&Aディール及び事業提携情報
    Summary Healthland Inc (Healthland), a subsidiary of Computer Programs and Systems Inc, is a healthcare technology company that develops EHR solutions. The company offers services such as cloud services, implementation services, infrastructure services, professional services, revenue cycle managemen …
  • Datatec Limited:企業の戦略・SWOT・財務分析
    Datatec Limited - Strategy, SWOT and Corporate Finance Report Summary Datatec Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Imdex Ltd (IMD):企業の財務・戦略的SWOT分析
    Imdex Ltd (IMD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Carrols Restaurant Group, Inc.:企業の戦略・SWOT・財務情報
    Carrols Restaurant Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Carrols Restaurant Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Noni B Ltd (NBL):企業の財務・戦略的SWOT分析
    Noni B Ltd (NBL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • ASML Holding N.V.:企業の戦略・SWOT・財務情報
    ASML Holding N.V. - Strategy, SWOT and Corporate Finance Report Summary ASML Holding N.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Saia Inc (SAIA):企業の財務・戦略的SWOT分析
    Saia Inc (SAIA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • American Airlines Group Inc (AAL):企業の財務・戦略的SWOT分析
    American Airlines Group Inc (AAL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • San Miguel Brewery Inc:企業の戦略・SWOT・財務情報
    San Miguel Brewery Inc - Strategy, SWOT and Corporate Finance Report Summary San Miguel Brewery Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Waters Corporation (WAT)-医療機器分野:企業M&A・提携分析
    Summary Waters Corporation (Waters) is an analytical instrument manufacturing company. It carries out the design, production, commercialization and servicing of analytical technologies such as high performance liquid chromatography (HPLC), ultra-performance liquid chromatography (UPLC), chromatograp …
  • Arris International Plc:企業の戦略・SWOT・財務情報
    Arris International Plc - Strategy, SWOT and Corporate Finance Report Summary Arris International Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • IV Diagnostics Inc-医療機器分野:企業M&A・提携分析
    Summary IV Diagnostics Inc (IV Diagnostics) is a biomedical company that offers research services. The company conducts molecular diagnostic tests for circulating tumor cells and other blood borne diseases. It develops, tests and markets diagnostic tools that monitor and measure cancer tumor cells. …
  • Avacta Group Plc (AVCT):企業の製品パイプライン分析2018
    Summary Avacta Group Plc (Avacta) is a developer therapeutic molecules used in a wide range of life sciences applications in research and diagnostics. The company offers products that include optim and sensipod. It also develops UCB celltech that is an analytical instrument. Avacta’s sensipod is an …
  • Cooper Tire & Rubber Company:企業の戦略・SWOT・財務情報
    Cooper Tire & Rubber Company - Strategy, SWOT and Corporate Finance Report Summary Cooper Tire & Rubber Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆